Oncimmune Holdings PLC (AIM:ONC) received a Queen's Award for Enterprise 2022 in the innovation category.
The award recognises Oncimmune as a leading developer of applied immunodiagnostics for the early detection of disease, drug discovery and development, the company said in a statement.
Adam Hill, chief executive, added: “We are delighted to be recognised for the progress we have achieved in oncology, other auto-immune and infectious diseases.
"Oncimmune has established a world-leading position in autoantibody-enabled immunodiagnostics and we are honoured to have our truly innovative approach recognised by the prestigious Queen's Award for Enterprise 2022.
“Since our inception, the mission for Oncimmune has been to use our extensive understanding of the immune system to enable us to harness its sophisticated response to disease in order to detect cancer earlier and to support the development of better therapies."